Gastroenterology Research and Practice / 2012 / Article / Tab 1 / Research Article
A Real World Report on Intravenous High-Dose and Non-High-Dose Proton-Pump Inhibitors Therapy in Patients with Endoscopically Treated High-Risk Peptic Ulcer Bleeding Table 1 Univariate analysis of demographic and clinical characteristics of non-rebleeding and rebleeding patients.
Variables Non-rebleeding group (
) Rebleeding group (
) P -valueAge (years)
0.941 Female gender,
(%) 50 (28.2) 21 (48.8) 0.010* Creatinine (mg/dL)
<0.001* Hb (g/L)
0.074 Platelet (×109 /L)
0.113 Use of NSAIDs,
(%) 12 (6.8) 2 (4.7) 0.608 Use of aspirin,
(%) 31 (17.5) 1 (2.3) 0.011* Use of clopidogrel,
(%) 18 (10.2) 5 (11.6) 0.779 Use of warfarin,
(%) 7 (4.0) 3 (7.0) 0.393 Coexisting illness,
(%) CKD III to V 73 (41.2) 26 (60.5) 0.013* COPD 6 (3.4) 5 (11.6) 0.026* CAD 29 (16.4) 8 (18.6) 0.727 DM 48 (27.1) 18 (41.9) 0.058 CVA 26 (14.7) 8 (18.6) 0.524 Liver cirrhosis 32 (18.1) 7 (16.3) 0.782 High stigmata,
(%) 173 (97.7) 41 (95.3) 0.388 Forrest classification Ia/Ib/IIa/IIb/IIc/III 9/100/18/45/5/0 5/31/1/5/0/1 Shock on admission,
(%) 89 (50.3) 23 (53.5) 0.706 Rockall score
,
(%) 105 (59.3) 36 (83.7) 0.003* Time to endoscope (h)
0.129 Hemostasis methods A/B/C/D/E/F 62/48/11/50/2/4 11/14/0/15/2/1 Ulcer size (cm)
0.973 Multiple ulcers,
(%) 58 (32.8) 18 (41.9) 0.261 PRBC BT (mL)
<0.001* Surgery,
(%) 0 2 (4.7) 0.004* Hospital stay (days)
<0.001* Mortality,
(%) 8 (4.5) 9 (20.9) 0.001* Bleeding related/other causes 1/7 3/6
PPI: proton-pump inhibitors, Hb: hemoglobin, CKD: chronic kidney disease, NSAID: nonsteroidal anti-inflammatory drug, PPI: proton-pump inhibitor, DM: diabetes mellitus type 2, COPD: chronic obstructive pulmonary disease, CAD: coronary artery disease, CVA: cerebrovascular accident, BT: blood transfusion, PPI: proton pump inhibitor, Hemostasis methods A/B/C/D/E/F: Bosmin plus APC/heat probe=A, APC/heat probe=B, Hemoclip=C, Bosmin plus hemoclip=D, APC/heat probe plus hemoclip=E, APC plus hemoclip plus Bosmin=F, APC: argon plasma coagulation. *
.